- About the Center
- Research Programs
- Addiction Genetics and Pharmacogenetics Division
- Addiction Treatment and Medication Development Division
- Brain-Behavioral Vulnerabilities Laboratory
- HIV/AIDS Prevention Research Division
- Clinical Trials Network
- Novel Interventions in Criminal Justice Populations Division
- Continuing Care and Assessment Division
- Integrated Care for Primary Care
- Clinical Trial Participation
- Treatment Options
- Affiliated Divisions
- Center Faculty
- Post Doctoral Fellowships
- Recorded Seminars
- Public Education and Policy Work
- Contact Us
- Support Our Work
Henry Kranzler, MD
Additional Information & Contact: Dept. of Psychiatry link
Kranzler HR, Covault J, Feinn R, Armeli S, Tennen T, Arias AJ, Gelernter J, Oncken C, Pond T, Kampman KM. Topiramate treatment for heavy drinkers: Moderation by a GRIK1 polymorphism, American Journal of Psychiatry, 171: 445-452, 2014. (PMCID: PMC3997125).
Kranzler HR, Armeli, Wetherill R, Feinn R, Tennen H, Gelernter J, Covault J, Pond T. Self-efficacy mediates the effects of topiramate and GRIK1 genotype on drinking. Addiction Biology, 21:450-9, 2016 (PMCID: PMC4468044).
Smith AH, Jensen KP, Li J, Nunez Y, Farrer LA, Hakonarson H, Cook-Sather SD, Kranzler HR, Gelernter J. Genome-wide association study of therapeutic opioid dosing identifies a novel locus upstream of OPRM1. Molecular Psychiatry, 22: 346-352, 2017 (PMCID: PMC28115739).
Grants & Funding
- Co-Principal Investigator on Million Veterans Program grant I01 BX003341 01: Genetic Vulnerability for Sustained Multi-Substance Use in MVP.
- National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Ondansetron treatment of alcohol dependence” (R01 AA021164)
- National Institute on Alcohol Abuse and Alcoholism. Principal Investigator for “Pharmacogenetic analysis of topiramate treatment of AUD” (R01 AA023192)
- National Cancer Institute. Principal Investigator for “Placebo-controlled trial of bupropion for smoking cessation in pregnant women” (R01 CA184315)
Henry R. Kranzler, M.D. is Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania’s Perelman School of Medicine. His research focuses on the genetics and pharmacological treatment of substance dependence, with a particular emphasis on precision addiction medicine. His research has been continuously supported since 1987 by grants from the National Institutes of Health. He has authored or co-authored more than 500 journal articles, book chapters, and books, is a member of the editorial board of five peer-review journals, and is the Editor of Alcoholism: Clinical and Experimental Research. His work currently focuses on the molecular genetics of substance dependence and the personalized treatment of alcohol, opioid, and nicotine use disorders using a pharmacogenetic approach.
Back to Top